Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.

Trial Details

NCT ID

NCT03753243

Phase

PHASE2

Sponsor

Mark Garzotto, MD

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Pembrolizumab
Enzalutamide

Locations (sample)

Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

Be willing and able to provide written informed consent/assent for the trial.
Capability to understand and comply with the protocol and signed informed consent document.
Be ≥ 18 years of age on day of signing informed consent.
Have measurable disease based on RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →